Cite
Sano A, Sohda M, Nakazawa N, et al. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer. 2022;22(1):22doi: 10.1186/s12885-021-09118-3.
Sano, A., Sohda, M., Nakazawa, N., Ubukata, Y., Kuriyama, K., Kimura, A., Kogure, N., Hosaka, H., Naganuma, A., Sekiguchi, M., Saito, K., Ogata, K., Sakai, M., Ogawa, H., Shirabe, K., & Saeki, H. (2022). Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC cancer, 22(1), 22. https://doi.org/10.1186/s12885-021-09118-3
Sano, Akihiko, et al. "Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study." BMC cancer vol. 22,1 (2022): 22. doi: https://doi.org/10.1186/s12885-021-09118-3
Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer. 2022 Jan 03;22(1):22. doi: 10.1186/s12885-021-09118-3. PMID: 34980017; PMCID: PMC8721909.
Copy
Download .nbib